The immunosuppressive drug mizoribine directly prevents podocyte injury in puromycin aminonucleoside nephrosis

Nephron - Experimental Nephrology

Volumn 116, Issue 1, 2010, Pages

  Takeuchi, Shigeru ^a   Hiromura, Keiju ^a   Tomioka, Mai ^a   Takahashi, Satoshi ^a   Sakairi, Toru ^a   Maeshima, Akito ^a   Kaneko, Yoriaki ^a   Kuroiwa, Takashi ^a   Nojima, Yoshihisa ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Mizoribine; Podocyte; Proteinuria; Puromycin aminonucleoside

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; INOSINATE DEHYDROGENASE; INTEGRIN LINKED KINASE; MIZORIBINE; NEPHRIN; PUROMYCIN AMINONUCLEOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOFLUORESCENCE; KIDNEY INJURY; MALE; NEPHROSIS; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RAT; RENAL PROTECTION;

ANIMALS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MALE; MEMBRANE PROTEINS; NEPHROSIS; PODOCYTES; PROTEIN-SERINE-THREONINE KINASES; PUROMYCIN AMINONUCLEOSIDE; RATS; RATS, WISTAR; RIBONUCLEOSIDES;

EID: 77952488666     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314668     Document Type: Article

References (30)

1. Mizuno K, Tsujino M, Takada M, Hayashi M, Atsumi K: Studies on bredinin. I. Isolation, characterization and biological properties. J Antibiot (Tokyo) 1974; 27: 775-782.
2. Sakaguchi K, Tsujino M, Yoshizawa M, Mizuno K, Hayano K: Action of bredinin on mammalian cells. Cancer Res 1975; 35: 1643-1648.
3. Stypinski D, Obaidi M, Combs M, Weber M, Stewart AJ, Ishikawa H: Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol 2006; 63: 459-468.
4. Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H, Tanizawa T, Wada H, Maki S: A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000; 58: 317-324.
5. Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, Shiiki H, Makino H, Sato H, Ishikawa I, Maeda K, Tomita K, Arakawa M, Ishida M, Sato M, Nagase M, Kashihara N, Yorioka N, Koike T, Saito T, Harada T, Mitarai T, Sugisaki T, Nagasawa T, Tomino Y, Nojima Y, Kobayashi Y, Sakai O: A randomized open-label comparative study of conventional therapy versus mizoribine onlay therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol 2004; 8: 117-126.
6. Kawasaki Y, Hosoya M, Kobayashi S, Ohara S, Onishi N, Takahashi A, Isome M, Suzuki H: Oral mizoribine pulse therapy for patients with steroid-resistant and frequently relapsing steroid-dependent nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 2243-2247.
7. Fujieda M, Ishihara M, Morita T, Hayashi A, Utsunomiya Y, Ohta T, Sakano T, Wakiguchi H: Effect of oral mizoribine pulse therapy for frequently relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 2008; 69: 179-184.
8. Doi T, Masaki T, Shiraki N, Kawai T, Yorioka N: Oral mizoribine pulse therapy for steroiddependent focal segmental glomerulosclerosis. Clin Nephrol 2008; 69: 433-435.
9. Shibasaki T, Matsuda H, Gomi H, Usui M, Ishimoto F, Sakai O: Mizoribine reduces urinary protein excretion in rats given puromycin aminonucleoside. Am J Nephrol 1996; 16: 167-172.
10. Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ: Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: role of p53 and bcl-2-related family proteins. J Am Soc Nephrol 2005; 16: 2615-2625.
11. Hagiwara M, Yamagata K, Capaldi RA, Koyama A: Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int 2006; 69: 1146-1152.
12. Shibata S, Nagase M, Fujita T: Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 2006; 17: 754-764.
13. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 1997; 236: 248-258.
14. Sakairi T, Hiromura K, Yamashita S, Takeuchi S, Tomioka M, Ideura H, Maeshima A, Kaneko Y, Kuroiwa T, Nangaku M, Takeuchi T, Nojima Y: Nestin expression in the kidney with an obstructed ureter. Kidney Int 2007; 72: 307-318.
15. Steinmetz OM, Panzer U, Fehr S, Meyer-Schwesinger C, Stahl RA, Wenzel UO: A pitfall of glomerular sieving: profibrotic and matrix proteins derive from the Bowman's capsule and not the glomerular tuft in rats with renovascular hypertension. Nephrol Dial Transplant 2007; 22: 3055-3060.
16. Koshikawa M, Mukoyama M, Mori K, Suganami T, Sawai K, Yoshioka T, Nagae T, Yokoi H, Kawachi H, Shimizu F, Sugawara A, Nakao K: Role of p38 mitogen-activated protein kinase activation in podocyte injury and proteinuria in experimental nephrotic syndrome. J Am Soc Nephrol 2005; 16: 2690-2701.
17. Griffin SV, Hiromura K, Pippin J, Petermann AT, Blonski MJ, Krofft R, Takahashi S, Kulkarni AB, Shankland SJ: Cyclin-dependent kinase 5 is a regulator of podocyte differentiation, proliferation, and morphology. Am J Pathol 2004; 165: 1175-1185.
18. Mitchell BS, Dayton JS, Turka LA, Thompson CB: Imp dehydrogenase inhibitors as immunomodulators. Ann NY Acad Sci 1993; 685: 217-224.
19. Ishikawa H: Mizoribine and mycophenolate mofetil. Curr Med Chem 1999; 6: 575-597.
20. Tam RC, Lau JY, Hong Z: Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 2001; 12: 261-272.
21. Kretzler M, Teixeira VP, Unschuld PG, Cohen CD, Wanke R, Edenhofer I, Mundel P, Schlondorff D, Holthofer H: Integrin-linked kinase as a candidate downstream effector in proteinuria. FASEB J 2001; 15: 1843-1845.
22. Nakajo A, Khoshnoodi J, Takenaka H, Hagiwara E, Watanabe T, Kawakami H, Kurayama R, Sekine Y, Bessho F, Takahashi S, Swiatecka-Urban A, Tryggvason K, Yan K: Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol 2007; 18: 2554-2564.
23. Teixeira Vde P, Blattner SM, Li M, Anders HJ, Cohen CD, Edenhofer I, Calvaresi N, Merkle M, Rastaldi MP, Kretzler M: Functional consequences of integrin-linked kinase activation in podocyte damage. Kidney Int 2005; 67: 514-523.
24. Matsui I, Ito T, Kurihara H, Imai E, Ogihara T, Hori M: Snail, a transcriptional regulator, represses nephrin expression in glomerular epithelial cells of nephrotic rats. Lab Invest 2007; 87: 273-283.
25. Wu C, Dedhar S: Integrin-linked kinase (ILK) and its interactors: a new paradigm for the coupling of extracellular matrix to actin cytoskeleton and signaling complexes. J Cell Biol 2001; 155: 505-510.
26. Dedhar S: Cell-substrate interactions and signaling through ILK. Curr Opin Cell Biol 2000; 12: 250-256.
27. Huelsken J, Birchmeier W: New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 2001; 11: 547-553.
28. Itoh H, Komatsuda A, Wakui H, Miura AB, Tashima Y: Mammalian HSP60 is a major target for an immunosuppressant mizoribine. J Biol Chem 1999; 274: 35147-35151.
29. Barazi HO, Zhou L, Templeton NS, Krutzsch HC, Roberts DD: Identification of heat shock protein 60 as a molecular mediator of alpha 3 beta 1 integrin activation. Cancer Res 2002; 62: 1541-1548.
30. Takahashi S, Wakui H, Gustafsson JA, Zilliacus J, Itoh H: Functional interaction of the immunosuppressant mizoribine with the 14-3-3 protein. Biochem Biophys Res Commun 2000; 274: 87-92.